Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear. Methods In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes. Results Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial included nearly 20% of people with diabetes and noted decreased cardiovascular events with treatment of hypertension to a systolic blood pressure goal of <130 mmHg (39).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [39]
In the citing paper
“Participants with diabetes comprised nearly 20% of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial, which noted decreased cardiovascular events with treatment of hypertension to a systolic blood pressure goal of <130 mmHg (41).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [41]
In the citing paper
“Hypotension occurred more frequently in the intensive treatment group (3.4%) compared with the standard treatment group (2.6%), without signi fi cant differences in other adverse events, including dizziness, syncope, or fractures.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [34]
In the citing paper
“In this trial, the primary composite outcome of stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fi brillation, or death from cardiovascular causes was reduced by 26% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [34]
In the citing paper
“In this trial, 18.9% of patients in the intensive treatment arm and 19.4% in the standard treatment arm had a diagnosis of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [34]
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Cited by
Items 201–300 of 805
Sarcopenia as a risk factor for hypertension
Toba, A., & Ishikawa, J. (2024) · Hypertension Research · doi:10.1038/s41440-024-01898-y · Cited by 11
Khan, S. S., Abdalla, M., Bello, N. A., Blyler, C. A., Carter, J., Commodore-Mensah, Y. Y., Ferdinand, K. C., Johnson, H. M., Jones, D. W., Khera, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001355 · Cited by 15
Updates in the 2025 AHA/ACC Hypertension Guideline
Brown, C. A., Clark, D., & Jones, D. W. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01372-9 · Cited by 13
Wu, M., Ying, W., Chen, W., Kaizu, X., Song, M., & Lin, L. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10338-x · Cited by 14
Intensive blood pressure control on arterial stiffness among older patients with hypertension
Zhang, ., Zhong, Y., Wu, S., Wu, H., Cai, J., Zhang, W., & On behalf of the STEP Study Group (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002868 · Cited by 11
“[11] Office blood pressure measurements were performed by a trained trial staff member (physician or nurse).”
BackgroundMethodResultInfluentialSelf-citationGender differences in acute aortic syndromes
Bhatt, N., & Chung, J. C.-Y. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001012 · Cited by 11
Population-based approaches to increase hypertension control: an urgent need
Richardson, C., Battle, S. J., & DiPette, D. J. (2024) · Hypertension Research · doi:10.1038/s41440-024-02022-w · Cited by 11
“…evaluated for the primary outcome of systolic blood pressure (SBP) control with secondary outcomes including BP control rate (<140/90 mmHg), excess BP reduction rates based on the STEP trial [15] (>3 BP readings of SBP 110), and the rate of use of the iHEC application by the intervention group.”
Lauinger, A. R., & Sepe, J. J. (2025) · Biomedicines · doi:10.3390/biomedicines13010171 · Cited by 11
“Understanding the relationship of these diseases”
Hassan, S., Blood, A. J., Zelle, D., Kumar, S., Wagholikar, K. B., Gabovitch, D., Cannon, C. P., Fisher, N. D. L., & Scirica, B. M. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24475 · Cited by 11
Giannas, E., Patel, A., Dias, P., Heath, R. J., Sinclair, R. C. F., Surman, K., Milton, A., Middleditch, A., Abbott, T. E. F., Ackland, G. L., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.06.026 · Cited by 10
Alsalloum, M. A., Albekery, M. A., & Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630160 · Cited by 12
Al‐Saleh, Y., Busaidi, N. A., Dahi, W. A. A., Almajnoni, M., Mohammed, A. S., Alshali, K. Z., Alshamiri, M. Q., Sifri, S. A., Arafah, M., Chan, S. P., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02529-7 · Cited by 12
Ou, Y.-H., Colpani, J. T., Chan, S., Loke, W., Cheong, C., Kong, W. K. F., Chin, C., Kojodjojo, P., Wong, P. E. H., Cistulli, P. A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072853 · Cited by 11
Does renal denervation require cardiovascular outcome-driven data?
Haider, S. A., Wagener, M., Iqbal, T., Shahzad, S., Sole, P. A. D., Leahy, N., Murphy, D., Sharif, R., Ullah, I., & Sharif, F. (2024) · Hypertension Research · doi:10.1038/s41440-024-01598-7 · Cited by 10
Blood pressure targets for hypertension in people with chronic renal disease
Erviti, J., Saiz, L. C., Leache, L., Pijoán, J. I., Orenga, M. M., Salzwedel, D. M., & Méndez-López, I. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008564.pub3 · Cited by 20
Controversies in Hypertension II: The Optimal Target Blood Pressure
Filippone, E. J., Foy, A., & Naccarelli, G. V. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.05.009 · Cited by 10
Lou, Y., Yu, Y., Liu, J., & Huang, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.959139 · Cited by 10
Fan, J., Zheng, W., Liu, W., Xu, J., Zhou, L., Liu, S., Bai, J., Qi, Y., Huang, W., Liu, K., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.20051 · Cited by 11
Self-citationSystolic Blood Pressure and Mortality in Community-Dwelling Older Adults: The Role of Frailty
Chen, C. L., Cai, A., Nie, Z., Huang, Y., & Feng, Y. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1850-4 · Cited by 10
Self-citationYang, R., Bai, J., Fang, Z., Wang, Y., Feng, Y., Liu, Y., Chi, H., Deng, Y., Song, Q., & Cai, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14927 · Cited by 10
Self-citationJin, Y., So, H., Cerin, E., Barnett, A. H., Mubarik, S., Hezam, K., Feng, X., Wang, Z., Huang, J., Zhong, C., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1035439 · Cited by 12
Self-citationMedical Telemonitoring for the Management of Hypertension in Older Patients in Japan
Fujiwara, T., Sheppard, J. P., Hoshide, S., Kario, K., & McManus, R. J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032227 · Cited by 14
Self-citationWang, Z., Yu, C., Cao, X., He, Y., & Ju, W. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14646 · Cited by 10
Cardiovascular Risk Factors in China
Hu, S. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.02.008 · Cited by 12
Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults
Reddy, T. K., Nasser, S. A., Pulapaka, A. V., Gistand, C. M., & Ferdinand, K. C. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02115-5 · Cited by 9
McFarlane, P., Madan, M., Ryschon, A. M., Tobe, S. W., Schiffrin, E. L., Padwal, R. S., Feldman, R. D., Dresser, G. K., Machan, L. S., Sadri, H., et al. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2441072 · Cited by 11
Optimizing cardiovascular pharmacotherapy in older adults with frailty
Nguyen, T. N., Woodward, M., Butt, J. H., McMurray, J. J. V., Lip, G. Y. H., & Kaski, J. C. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01244-w · Cited by 9
Multifaceted Strategies for Hypertension Control in Low-Income Patients
Mills, K. T., Krousel-Wood, M. A., Peacock, E. M., Chen, J., Allouch, F., Carreras, A. K., Geng, S., Cyprian, A., Davis, G., Fuqua, S. R., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2504068 · Cited by 12
Lee, D., Lee, J., Kim, S. Y., Lee, H., Choi, J., Hong, Y., Park, S. K., Ryu, D. R., Yang, D. H., Hwang, S., et al. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.067 · Cited by 9
Jiang, Y., Zheng, L., Zhang, Y., Fan, Z. Z., Guo, J., Yang, J., Liu, P., Zhong, P., & Xie, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01951-w · Cited by 9
Self-citationSarwal, A., Boucher, R. E., Hartsell, S. E., Wei, G., Shen, J., Chertow, G. M., Whelton, P. K., Cheung, A. K., McEvoy, J. W., Greene, T., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000539 · Cited by 9
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Qiu, W., Cai, A., Wu, S., Zhu, Y., Zheng, H., Nie, Z., Wang, J.-B., & Feng, Y. (2024) · Hypertension Research · doi:10.1038/s41440-024-02037-3 · Cited by 12
Self-citationPark, C. H., Kim, H. W., Park, J. T., Chang, T. I., Yoo, T., Oh, K., Anderson, A. H., Yang, W. P., Cohen, J. B., Rahman, M., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000760 · Cited by 10
Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases
Li, L., Hu, Z. Y., Xiong, Y., & Yao, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.803984 · Cited by 9
Management of hypertension associated with cardiovascular failure
Kiuchi, S., & Ikeda, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.11.012 · Cited by 9
Kario, K. (2025) · Hypertension Research · doi:10.1038/s41440-025-02355-0 · Cited by 11
Self-citationBrandão, A. A., Rodrigues, C. I. S., Bortolotto, L. A., Luna, L. C., Barros, B. M., Neves, M. F., Moura, A. F., Plavnik, F. L., Drager, L. F., Filho, O. M., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240761 · Cited by 8
Pop, C., Petriş, A. O., Pop, L., & David, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103269 · Cited by 10
“…to less than 120 mmHg versus less than 140 mmHg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomized trial), and the landmark BPROAD trial (Intensive Blood-Pressure Control in Patients with Type 2 Diabetes) [21–23].”
Hsu, R.-Y., Lo, H.-Y., Chen, C.-H., Wu, Y.-J., Chan, D., Wu, C., Wang, T., Kao, H., Sun, W., Lin, Y., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.05.007 · Cited by 8
Self-citationGoupil, R., Tsuyuki, R. T., Santesso, N. A., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A. C., Campbell, N. R. C., et al. (2025) · Canadian Family Physician · doi:10.46747/cfp.20250616001 · Cited by 9
Tang, Y., Zhang, Z., & Liu, X. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06204-0 · Cited by 8
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Arterial hypertension - clinical trials update 2022
Götzinger, F., Kunz, M., Lauder, L., Böhm, M., & Mahfoud, F. (2022) · Hypertension Research · doi:10.1038/s41440-022-00931-2 · Cited by 9
2022 Thai Hypertension Society guidelines on home blood pressure monitoring
Kunanon, S., Roubsanthisuk, W., Chattranukulchai, P., Sangwatanaroj, S., Ophascharoensuk, V., Sitthisook, S., & Sukonthasarn, A. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14569 · Cited by 11
Acute Declines in Estimated GFR in Blood Pressure Target Trials and Risk of Adverse Outcomes
Ku, E., McCulloch, C. E., Copeland, T. P., Inker, L. A., Tighiouart, H., & Sarnak, M. J. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.03.013 · Cited by 8
Zhao, B., Jia, W., Yuan, Y., Li, Z., & Fu, X. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107289 · Cited by 9
Influence of multiple risk factor control level on cardiovascular outcomes in hypertensive patients
Peng, X., Zhuang, M., Song, Q., Bai, J., & Cai, J. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae056 · Cited by 9
Self-citationPrimary Prevention of Ischemic Stroke
Sabayan, B. (2022) · Seminars in Neurology · doi:10.1055/s-0042-1758703 · Cited by 10
Kim, H., Shahbal, H., Parpia, S., Averbuch, T., Spall, H. G. C. V., Thabane, L., & Ma, J. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.05.015 · Cited by 8
Yu, J., Arnott, C. G., Li, Q., Tanna, G. L. D., Tian, M., Huang, L., Yin, X., Zhang, X., Pearson, S., Labarthe, D. R., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22410 · Cited by 9
Self-citationQiu, W., Cai, A., Zhiqiang, N., Wang, J.-B., Ou, Y., & Feng, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15653 · Cited by 9
Self-citationMaruhashi, T., & Higashi, Y. (2022) · Hypertension Research · doi:10.1038/s41440-022-00936-x · Cited by 9
New wrinkles in hypertension management 2022
Carey, R. M., & Whelton, P. K. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000980 · Cited by 8
Monitorização Residencial da Pressão Arterial e Controle Pressórico em Hipertensos Tratados
Brandão, A. A., Barroso, W. K. S., Feitosa, A. D. M., Barbosa, E. C. D., Miranda, R. D., Vitorino, P. V. D. O., Pozzan, R., Ribeiro, L. P. D. S., Epelman, A., Saraiva, G. A., et al. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20220038 · Cited by 8
Jo, S., Kang, S., Yoo, B., Lee, Y. S., Youn, H., Min, K. W., Yu, J. M., Yoon, H. J., Kim, W. S., Kim, G.-H., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020350 · Cited by 8
Highlights in ASCVD Primary Prevention for 2021
Polonsky, T. S., Khera, A., Miedema, M. D., Schocken, D. D., & Wilson, P. W. F. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025973 · Cited by 9
Moving the Goalposts for Blood Pressure — Time to Act
Nelson, M. R. (2021) · New England Journal of Medicine · doi:10.1056/nejme2112992 · Cited by 8
How Low Should You Go in the Presence of Frailty?
Odden, M. C., & Anderson, T. S. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18373 · Cited by 8
Sacubitril/valsartan—A new weapon for fighting the hypertension paradox
Ohishi, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00872-w · Cited by 8
Hypertension management to prevent dementia
Mogi, M. (2022) · Hypertension Research · doi:10.1038/s41440-022-00869-5 · Cited by 9
Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia
Sarnaik, K. S., & Mirzai, S. (2025) · Journal of Vascular Diseases · doi:10.3390/jvd4020018 · Cited by 13
“The results of the STEP trial demonstrated a 26% risk reduction of the primary outcome among participants in the intensive treatment arm relative to those in the standard treatment arm [20].”
InfluentialArterial stiffness moderates the link between NfL and cognition: The IGNITE study
Norling, A. M., Lipsitz, L. A., Dufour, A. B., Travison, T. G., Sewell, K. R., Collins, A. M., Wan, L., Grove, G., Huang, H., Oberlin, L. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70554 · Cited by 7
Cai, J., Zheng, D., Xu, S., Jiang, S., Jiang, Y., Zhang, R., Li, C., Zhang, L., & Wang, B. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02007-w · Cited by 8
Self-citationGao, Q., & Ji, Y. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2662627 · Cited by 1
Lee, E. M., Cho, I., Kang, H., Kim, K., Kim, D., Kim, J. H., Kim, H., Kim, H. C., Kim, H. J., Koh, E. S., et al. (2026) · Clinical Hypertension · doi:10.5646/ch.2026.32.e31 · Cited by 7
Reddin, C., Murphy, R., Hanrahan, C., Loughlin, E. A., Ferguson, J. P., Judge, C. S., Waters, R., Canavan, M. D., Kenny, R. A., & O'Donnell, M. J. (2023) · Age and Ageing · doi:10.1093/ageing/afad044 · Cited by 8
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 9
Briones‐Valdivieso, C., Salerno, P. R. V. D. O., Navarrete‐Muñoz, E. M., Valera‐Gran, D., López‐Bueno, R., Al-Kindi, S. G., Deo, S. V. S., & Petermann-Rocha, F. E. (2024) · Public Health · doi:10.1016/j.puhe.2024.06.039 · Cited by 7
Razavi, A. C., Troy, A. L., Patel, J., Mehta, L. S., Spitz, J. A., Lloyd‐Jones, D. M., Whelton, S. P., Johansen, M. C., & Blumenthal, R. S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101724 · Cited by 8
Ridgway, H. F., Moore, G. J., Gadanec, L. K., & Matsoukas, J. (2025) · Biomolecules · doi:10.3390/biom15060855 · Cited by 7
“Angiotensin receptor blockers (ARBs), such as sartans, have long been established for their efficacy in managing hypertension and cardiovascular diseases [1,2].”
Pan‐risk factor for a comprehensive cardiovascular health management
Zheng, R., Xu, Y., Li, M., Lu, J., Xu, M., Wang, T., Zhao, Z., Wang, S., Lin, H., Zhang, X., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13258 · Cited by 9
Self-citationTight Blood Pressure Control in Chronic Kidney Disease
Gentile, G., Mckinney, K., & Reboldi, G. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050139 · Cited by 8
Farag, S. M., Rabea, H., Abdelrahim, M. E. A., & Mahmoud, H. B. (2022) · Current Hypertension Reviews · doi:10.2174/1573402118666220627120254 · Cited by 8
A nationwide study of multimedicine use in people treated with cardiovascular medicines in Australia
Schaffer, A. L., Chia, J., Brett, J., Pearson, S., & Falster, M. O. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2735 · Cited by 8
Fan, J., Bai, J., Liu, W., & Cai, J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1042637 · Cited by 10
Self-citationTong, P. C.-Y., Chan, S. C.-P., Chan, W. B., Ho, K. K. L., Leung, G. T.-C., Lo, S. H.-K., Mak, G. Y. K., & Tse, T.-S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103403 · Cited by 8
Shin, J., Wang, J., Chia, Y. C., Kario, K., Chen, C., Cheng, H., Fujiwara, T., Hoshide, S., Minh, H. V., Li, Y., et al. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14729 · Cited by 8
Self-citationWhich blood pressure metrics should be used in patients on dialysis?
Jung, J. Y. (2023) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.23.126 · Cited by 8
Selected highlights in the updated treatment of hypertension
Creegan, D., & McEvoy, J. W. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.11.001 · Cited by 7
Chen, J., Huang, K., Lin, Y., Chueh, S., Wang, H., & Wu, V. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad709 · Cited by 7
Triglyceride glucose index as a biomarker for heart failure risk in H-type hypertension patients
Xu, Z., Yan, X., Li, D., & Huang, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-89211-w · Cited by 11
Self-citationTso, J., & Kim, J. H. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2022.08.002 · Cited by 7
Leong, D. P., Rangarajan, S., Rosengren, A., Oğuz, A., AlHabib, K. F., Poirier, P., Díaz, R., Dans, A. L., Iqbal, R., Yusufali, A., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac069 · Cited by 7
Brunström, M., Carlberg, B., & Kjeldsen, S. E. (2023) · Blood Pressure · doi:10.1080/08037051.2023.2226757 · Cited by 9
Ohkubo, T. (2021) · Hypertension Research · doi:10.1038/s41440-021-00765-4 · Cited by 7
Another Nail in the Coffin of Causality for the Diastolic Blood Pressure J Curve
Birrane, J. P., Foschi, M., Sacco, S., & McEvoy, J. W. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.18997 · Cited by 7
Hypertension paradox in Japan: the road ahead
Shibata, S. (2023) · Hypertension Research · doi:10.1038/s41440-023-01414-8 · Cited by 7
Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges
Bond, R. M., Purewal, V. S., Cameron, N. A., Tobb, K., Adedinsewo, D. A., Isiadinso, I., & Phillips, K. A. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01362-x · Cited by 6
Erhöhter Blutdruck und Bluthochdruck: ESC-Leitlinie 2024 rückt Risikoreduktion in den Fokus
Schmieder, R. S., & Schunkert, H. (2024) · Herz · doi:10.1007/s00059-024-05285-8 · Cited by 7
Kahan, T., Johansen, M. L., Ryschon, A. M., Cao, K. N., Kolovetsios, M., Lindgren, P., & Pietzsch, J. B. (2025) · Blood Pressure · doi:10.1080/08037051.2025.2487583 · Cited by 8
Benefit and Harm of Intensive Blood Pressure Control by Cardiovascular Risk
Dong, X., Ling, Q., Zhao, X., Song, Q., & Cai, J. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25162 · Cited by 6
Self-citationDerington, C. G., Berchie, R. O., Greene, T., Jacobs, J. A., Moran, A. E., Xu, Y., Narita, K., Zheutlin, A. R., Cohen, J. B., Shimbo, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.037 · Cited by 7
Hypertension in the Oldest Old
Supiano, M. A., Ascher, S. B., & Rich, M. W. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102306 · Cited by 9
Cheema, M. F., Butt, Z., Gilani, S., Shafiq, S., Cheema, S. U. R., & Das, M. K. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad039 · Cited by 6
Setting new research in the context of previous research: some options
Glasziou, P., Jones, M., & Clarke, M. J. (2023) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2023-112300 · Cited by 6
Chen, P., Zhang, W., Qi, J., Yang, B., Fan, Z., Chen, Y., Yu, X., Chen, H., & Wang, H. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-07753-y · Cited by 6
Self-citationSatoh, M., Metoki, H., Murakami, T., Tatsumi, Y., Asayama, K., Kikuya, M., Ohkubo, T., & Imai, Y. (2024) · Hypertension Research · doi:10.1038/s41440-024-01954-7 · Cited by 7
Yang, H., Xing, H., Zou, X., Jin, M., Li, Y., Xiao, K., Li, C., Liu, Y., & Yang, X. (2025) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2025.2465399 · Cited by 6
Self-citation
Metadata
- Authors
- Zhang, W., Zhang, S., Deng, Y., Wu, S., Ren, J., Sun, G., Yang, J., Jiang, Y., Xu, X., Wang, T.-D., Chen, Y., Li, Y., Yao, L., Li, D., Wang, L., Shen, X., Yin, X., Liu, W., Zhou, X., Zhu, B., Guo, Z., Liu, H., Chen, X., Feng, Y., Tian, G., Gao, X., Kario, K., & Cai, J.
- Affiliations
- Shanxi Medical University (CN)
- Hebei North University (CN)
- Omron (Japan) (JP)
- Jichi Medical University (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-30
- Volume
- 385
- Issue
- 14
- Pages
- 1268-1279
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3198533772
- Cited by
- 784
- References
- 47
- Citations by year
- 2026: 131 · 2025: 196 · 2024: 146 · 2023: 134 · 2022: 154 · 2021: 23
- FWCI
- 76.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81630014, 81825002)
- Beijing Outstanding Young Scientist Program (BJJWZYJH01201910023029)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-I2M-1-006, CI2021A00920)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- intensive blood pressure control, systolic blood pressure target, older adults, hypertension, cardiovascular risk reduction, stroke, acute coronary syndrome, acute decompensated heart failure, coronary revascularization, atrial fibrillation, cardiovascular mortality, renal outcomes, antihypertensive therapy, Chinese patients, SPRINT trial
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Female, Humans, Hypertension, Hypotension, Male, Middle Aged, Systole, Incidence, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.